Opinion|Videos|September 4, 2024

Ravulizumab Long-Term Data and Management of NMOSD

This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.

Episodes in this series

Video content above is prompted by the following:

  • The 138-week data for ravulizumab, the most recently approved neuromyelitis optica spectrum disorder (NMOSD) treatment, was presented at the 2024 American Academy of Neurology Annual Meeting. What do we know about relapses while on ravulizumab in the long term?
  • Please share practical tips for management of NMOSD in the clinic.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Latest CME

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients
In-Person + Virtual Event

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

February 6, 2026

View more
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

View more
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

View more
Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier
Video

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

View more
A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden
Video

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

View more
PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)
Audio

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

View more
PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
Audio

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

View more